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Abstract. To improve the blood–brain barrier permeability of the trypanocidal lead 
compound 4,4'-bis(imidazolinylamino)diphenylamine (1), five N-alkoxy analogues 
were synthesized from bis(4-isothiocyanatophenyl)amine and N-alkoxy-N-(2-
aminoethyl)-2-nitrobenzenesulfonamides following successive chemical reactions in 
just one reactor (“one-pot procedure”). This involved: a) formation of a thiourea 
intermediate, b) removal of the amine protecting groups, and c) intramolecular 
cyclization. The blood–brain barrier permeability of the compounds determined in vitro 
by transport assays through the hCMEC/D3 human cell line, a well-known and 
characterized human cellular blood–brain barrier model, showed that the N-hydroxy 
analogue 16 had enhanced blood–brain barrier permeability compared with the un-
substituted lead compound. Moreover, this compound displayed low micromolar IC50 
against Trypanosoma brucei rhodesiense and Plasmodium falciparum, and moderate 
activity by intraperitoneal administration in the STIB900 murine model of acute 
sleeping sickness.  
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Introduction 
Human African trypanosomiasis (HAT‡ or sleeping sickness), a neglected tropical 
disease caused by subspecies of the protozoan parasite Trypanosoma brucei, is endemic 
in several regions of sub-Saharian Africa. It also represents a serious economic and 
social burden to some of Africa’s poorest countries.1 According to the last 
epidemiologic update by the World Health Organization (WHO),2 50000 to 70000 
people were infected in 2006. However, this may remain only a short-term view as no 
long-term systematic screening of the population at risk is currently ongoing.3 
Chemotherapy of HAT relies on four old drugs (suramin, pentamidine, melarsoprol and 
eflornithine) which have unacceptable toxicity and require parenteral administration. 
This, greatly complicates the treatment of patients in disease endemic countries with no 
basic health care systems.4, 5 The treatment options available for the late-stage disease 
involving central nervous system (CNS) infection are particularly deficient as they 
mostly rely on a highly toxic arsenical derivative, melarsoprol, which provokes deadly 
post-treatment reactive encephalopathy in up to 10% of the cases.4 Even though the 
recent inclusion of the combination therapy Nifurtimox-eflornithine as simplified stage 
2 treatment for T. b. gambiense sleeping sickness improves the therapeutic arsenal 
against late-stage HAT, the discovery of new orally active drugs that are able to cure the 
acute and CNS stages of HAT remains a priority in tropical medicine.1 
In previous reports, we have shown that 4,4'-bis(imidazolinylamino)diphenylamine 
dihydrochloride (1, Chart 1) displayed excellent antitrypanosomal6 and antiplasmodial7 
                                                 
‡ Abbreviations: BBB: blood-brain barrier; CNS: central nervous system; DMF: N,N-
dimethylformamide; DIPEA: N,N-diisopropylethylamine; EtOAc: ethyl acetate; Et2O: 
diethyl ether; HAT: human African trypanosomiasis; LY: lucifer yellow; Ns (nosyl): 2-
nitrobenzenesulfonamide. 
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activity in vitro. The crystal structure of 1 bound to its preferred DNA binding site 5’-
AATT has suggested a basis for understanding the antitrypanosomal action of this 
compound.8 Further studies in vivo have shown that this trypanocidal lead compound 
was curative by intraperitoneal administration in murine models of acute T. b. brucei 
and T. b. rhodesiense infections, but not in the late-stage disease involving CNS 
infection.9 A reason for the lack of effectiveness against the CNS-stage is a poor brain 
penetration that is most likely due to the positively charged imidazolinylamino groups 
(pKa = 9.9)
10 at physiological pH, which limit its passage through the blood-brain 
barrier (BBB). The same drawback has been observed with diamidine drugs such as 
pentamidine or diminazene which have been used for decades as a first line treatment 
for early stage gambiense sleeping sickness and cattle trypanosomiasis (Nagana), 
respectively. Previous reports in the literature have shown that derivatization of the 
amidine group as amidoxime prodrug was useful to overcome this problem and improve 
the oral bioavailibility and CNS delivery of diamidines. These amidoxime prodrugs are 
metabolized to the amidine active compounds through sequential oxidative O-
demethylation by cytochrome P450 isoforms 1A1, 1A2 and 1B1 and cytochrome b5 
catalyzed reductive N-dehydroxylation reactions.11-21 
More recently, similar prodrug strategies (e.g., N-substituted bis-C-
alkyloxadiazolones,22 N,N'-dihydroxyamidines,23 O-carboxymethylamidoximes,24 
diacetyldiamidoximeester25) for the oral delivery of amidines and guanidines were also 
reported. 
In line with these findings, we have developed a similar approach (i.e., synthesis of N-
alkoxy analogues) to reduce the pKa of the imidazolinylamino moiety in order to 
improve the pharmacokinetics of compound 1. We also sought to establish the influence 
of replacing the imidazolylamino moiety with a closely related heterocycle (i.e., 4,5-
 5 
dihydrothiazolinylamine) that has lower pKa value so as to avoid problems of being 
ionized at physiological pH (i.e., the pKa of thiazolines is ca. 3 units lower than the pKa 
of imidazolines; e.g., 2-aminoimidazole: pKa = 8.46;
26 2-aminothiazole, pKa = 5.39).
27 
Hence, five different N-alkoxy substituted analogues of 1 (Chart 1) and the 4,5-
dihydrothiazolinylamino derivative 17 (Scheme 2) were synthesized. The 
antitrypanosomal activity of the target compounds was checked in vitro against the 
STIB900 Trypanosoma brucei rhodesiense strain. As additional data, we also checked 
the antiprotozoal activity of the new  compounds against 3 related parasites 
(Trypanosoma cruzi, Leishmania donovani and Plasmodium falciparum).  
Further, the activity of the new compounds was assayed in vivo in the murine model of 
acute T. brucei infection. Additionally, the BBB permeability of the compounds was 
determined in vitro by permeability assays through the hCMEC/D3 human endothelial 
cell monolayer.28, 29 This cell line holds most of the specific properties of in vivo BBB, 
including cell-cell junction expression of tight junction proteins (claudin-5, JAM-A, Zo-
1) and the polarized expression of a variety of functional transporters.30, 31 By 
comparing the permeability coefficients of the new derivatives and the lead compound 
1, some conclusions regarding the influence of N-alkoxy substitution on the human 
BBB permeability can be drawn.  
Chart 1. Lead compound (1) and new N-alkoxy analogues. 
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16: R = OH  
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Results 
Chemistry. We attempted two different synthetic strategies in order to obtain the N-
alkoxy-substituted derivatives of 1. Both approaches relied on the reaction of two 
equivalents of a functionalized ethylenediamine precursor (4–5, or 9) with the 
isothiocyanate 3, previously prepared in 80% yield from 4,4’-diaminodiphenylamine 
(Scheme 1).32 The thiourea intermediates obtained (6–7, and 10–11, respectively) were 
subsequently subjected to intramolecular cyclization after adequate removal of the 
amine protecting groups.  
 
Scheme 1. Synthetic routes for the preparation of 1-alkoxy-2-arylaminoimidazolines 
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Regarding the first synthetic strategy, the N-alkoxyethylenediamine precursors 4, 5a, 
and 5b were prepared in low yield following the protocol previously described for 
compound 4 (Equation 1).33, 34 
RO NH2
Br NPht
DMF, 80ºC NH
NPhtRO
4: R = Bn (30-70%, 14 mmol scale)
5a: R = Me (20%, 4 mmol scale)
5b: R = Et (25%, 1.5 mmol scale)  
The reaction of 3 with 2.5 equivalents of 4, or 5a, gave 6 and 7, respectively (Scheme 
1). Attempts to optimize the conditions for the deprotection of the amino groups with 
hydrazine/EtOH and the subsequent in situ cyclization to the target compound 14 were 
disappointing, leading to several by-products. Hence, the thiourea 6 was activated via 
formation of the methylisothiouronium salt 8, which was obtained almost quantitatively 
(excess CH3I/ CH2Cl2/ rt / 24h) with a purity > 80%. Partial deprotection of one benzyl 
group accounted for the lower purity of the product. Longer reaction times slightly 
increased the yield of the deprotection product. Attempts of purification by 
chromatography were unsuccessful so the compound was used in the cyclization step 
without further purification. The deprotection of the amino groups (MeNH2/ THF-H2O) 
and the consequent in situ spontaneous cyclization afforded 14, which was isolated in 
40% yield after silica chromatography. Our attempts to scale up the synthesis of 5a and 
5b were unsuccessful so we explored a different strategy to obtain the corresponding 
methoxy 12 and ethoxy analogues 13. As an alternative, we considered the deprotection 
of the benzyl protecting groups of 14 and the subsequent alkylation of 16 to the 
corresponding alkoxy derivatives. However, all of the attempts to remove the benzyl 
groups, either by catalytic hydrogenolysis or by other classical methods,35 gave poor 
yields of the desired product. Hence, an alternative one-pot procedure strategy was 
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developed to prepare the 1-methoxy- (12), 1-ethoxy- (13), 1-benzyloxy- (14) and 1-
tetrahydropyranyloxy- (15) derivatives (Scheme 1).36 Treatment of 15 with HClg 
saturated dioxane solution afforded the 1-hydroxy analogue 16 as its dihydrochloride 
salt. The intermediates 10a and 10b were isolated in separate experiments and fully 
characterized.  
The 4,5-dihydrothiazolinylamino derivative 17 was prepared by reaction of 3 with 2-
bromoethanamine hydrobromide in the presence of triethylamine (Scheme 2). 
  
Scheme 2.a 
 
a  Reagents and conditions. (i) 2-bromoethanamine hydrobromide, Et3N, CH2Cl2, rt; (ii) 
HClg/dioxane, MeOH. 
  
In Vitro Antiprotozoal Activity. The target compounds (12–16, and 17) and the 
synthetic intermediates (6, 7, 10, and 11) were screened in vitro against T. b. 
rhodesiense and 3 other related parasites: T. cruzi, L. donovani and P. falciparum (Table 
1). The N-substituted compounds 12–16 showed submicromolar IC50 values against T. 
b. rhodesiense and P. falciparum. Nevertheless, these values represented a 5-fold (14, 
16), 10-fold (12, 13) and 20-fold (15) loss of activity against T. brucei, respectively, 
compared with the lead compound 1. The antiplasmodial activity was also decreased, in 
comparison with 1, by 20-fold (14), 50-fold (12, 13), 100-fold (15), and 7-fold for 
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compound 16. The latter notably conserved nanomolar activity (IC50 = 55 nM) and high 
selectivity (SI = 1673) against this parasite. Previous reports have underlined the 
importance of the positively charged imidazolylamino moieties of 1 for 
antitrypanosomal activity and for binding to DNA minor groove. 7-9 Hence, the 5- to 20-
fold higher IC50 observed in vitro for the uncharged 1-alkoxy-substituted derivatives 
12–16 was not unexpected. The lower activity of the 4,5-dihydrothiazolinylamino 
analogue 17 with respect to the imidazolylamino compound 1 (i.e., 160-fold against T. 
b. rhodesiense and 270-fold against P. falciparum) confirmed these findings. The higher 
pKa of the imidazoline structure (pKa = 9.9 for 1
10) ensures a higher proportion of the 
ionized form of the molecule at physiological pH, which proved important for high 
activity in this series. 
None of the new compounds showed significant activity against axenically grown 
amastigotes of L. donovani. On the contrary, one compound, 14, presented an IC50 value 
3-times higher than the reference drug benznidazole (1.64 µM) on intracellular T. cruzi 
amastigotes. The synthetic intermediates (urea derivatives) 6, 7, 10a, and 11b were 
poorly active on the four parasites with IC50 in the high micromolar range (Table 1). 
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Table 1. In Vitro Antiprotozoal Activity of N-substituted Analogues 12-17 and 
synthetic intermediates 6, 7, and 10.  
IC50 (µM) 
   
T. b. r.
a
 (SI)b T. c. (SI)c L. d. (SI)d P. f. (SI)e 
Cytotox. 
L6-cellsf 
Cmpd X R 
N
H
H
N
N
H
X
NN
X
R R  
1
g
 N H 0.069 (3072) nah na 0.009 (24091) 212 
12 N OMe 0.83 (65.6) 136 39 0.45 (120) 54 
13 N OEt 0.73 (55) 87 62 0.59 (68) 40 
14 N OBn 0.32 (34.7) 6.6 104 0.20 (56) 11 
15 N OTHP 1.18 (17) 24 41 0.75 (26) 20 
16 N OH 0.37 (236) > 204 58 0.055 (1673) 92 
17 S nil 11.1 (4.7) 30 120 2.43 (21) 52 
Cmpd R1 R2 
H
N
N
H
N
H
S
N
S
NR2 R2
R1 R1  
6 OBn -NPht 86.7 >100 36 1.36 >102 
7 OMe -NPht 73.8 >124 69 2.64 >124 
10a H -N(Ns)OMe 61.3 >108 68 1.81 >107 
10b H -N(Ns)OEt 14.9 >104 14 1.94 (35) 67 
 
a T. brucei rhodesiense STIB900 strain. Control: melarsoprol, IC50 = 12.6 nM; 
b 
Selectivity index = [IC50 (L6-cells) / IC50 (parasite)]; 
c Amastigotes of T. cruzi Tulahuen 
C4 strain. Control: benznidazole, IC50 = 1.64 µM; d L. donovani strain 
MHOM/ET/67/L82 axenically grown amastigotes. Control: miltefosine, IC50 = 0.275 
µM; e P. falciparum K1 erythrocytic stages. Control: chloroquine, IC50 = 0.169 µM; f 
Rat skeletal myoblast L-6 cells; g Data taken from ref. [6, 7]. h Not available. See 
reference [37] for detailed experimental procedures. 
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In Vivo Antitrypanosomal Activity. In the T. b. rhodesiense STIB900 mouse model of 
acute infection, which mimics the first stage of the disease, the lead compound 1 was 
curative when administered intraperitoneally at 4×20 mg/kg.9 However, it was hardly 
effective by oral route in this model (i.e., 10% increase in mean relapse days compared 
to control, no cures), and totally inactive in the GVR35 mouse model that mimics the 
late stage of the disease involving CNS infection.9 The newly synthesized N-alkoxy 
analogues of 1 were designed as possible prodrugs with improved oral bioavailability 
and enhanced CNS uptake. In order to check their in vivo activity, compounds 12–16 
were administered by intraperitoneal (4×20 mg/kg) and oral route (4×50 mg/kg) to T. 
brucei infected mice (Table 2). Compounds 12–15 did not show any activity in this 
model of first stage HAT (i.e., same mean time of relapse as the untreated mice), 
possibly due to a poor bioactivation in vivo. On the contrary, compound 16 was 
moderately active by ip administration increasing the mean time of relapse 3.6-fold 
compared to control. 
 
Table 2. In Vivo Antitrypanosomal Activity of N-substituted Analogs of 1 in the T. b. 
rhodesiense (STIB900) mouse model. 
Compound R 
Dosage 
routeb 
Dosage 
(mg/kg) 
Curedc/Infected 
Mean 
relapse days 
Control  - - 0/4 7d 
1 H 
ip 
po 
4 × 20 
4 × 50 
4/4e 
0/4 
> 60 
7.75 
12, 13, 14, 15 OMe, OEt, OBn, OTHP 
ip 
po 
4 × 20 
4 × 50 
0/4 
0/4 
7 
7 
16 OH 
ip 
po 
4 × 20 
4 × 50 
0/4 
0/4 
25.3 
7 
 12 
a See experimental section for details of STIB 900 (T. b. rhodesiense) model. b ip = 
intraperitoneal, po = per os. c Number of mice that survive and are parasite free for 60 
days. d Control mice were always positive and were euthanized on day 7. e Data taken 
from ref. [9]. 
 
In Vitro Determination of Human Blood-Brain Barrier Permeability. We have 
mentioned before that compound 1 did not show in vivo activity in the murine model of 
CNS-stage sleeping sickness.9 Because crossing the BBB is a requirement for drugs 
targeting the late-stage disease, we decided to assess the in vitro BBB permeability of 
the lead compound 1 and the new N-alkoxy analogues 12, 13, 14 and 16. The 
immortalized human brain endothelial cell line hCMEC/D329 was used for the drug 
transport studies. This cell line has proved useful as a human BBB model,28 so the 
results obtained in this study are particularly relevant from a therapeutic point of view. 
The clearance principle (i.e., the slope of the volume cleared versus time) was used to 
calculate the permeability coefficients as usually performed (see experimental part for 
details).38-40 The fluorescent dye lucifer yellow (LY) was used as a marker of passive 
diffusion through cell-cell junctions; a low permeability to LY reflects the integrity of 
the endothelial monolayer and the relevance of cell-cell junction complexes (see 
experimental part). First, we validated the good quality of the BBB model in the 
presence of the compounds by finding the concentration of the compounds which could 
be applied to the endothelial cells without affecting LY permeability. Hence, 
permeability assays of LY in the presence of the new compounds were performed. 
Compounds 1, 12, 13, and 16 did not affect the endothelial monolayer integrity (i.e., a 
low permeability to LY was conserved) at concentrations of 100 µM whereas 14 
required a concentration of 10 µM (Figure 1). Compound 14, at this concentration, 
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made the analysis of the results unreliable (i.e., beyond the sensitivity limits of our 
HPLC detection method). This suggests a very low permeability through the in vitro 
BBB for this compound.  
The measured permeability values for the lead compound (1), the O-methoxy (12), and 
O-ethoxy (13) derivatives were not significantly different from the one measured for the 
poorly permeable compound LY. In contrast, the 1-hydroxy analogue (16) had 
significant higher permeability than LY and also than compound 1 (nearly 3-fold). 
These results show that N-substitution of the imidazolylamino group with OH enhances 
the in vitro BBB permeability of this molecule whereas O-alkyl substituents do not 
improve the in vitro BBB permeability.  
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Figure 1. Endothelial monolayer integrity measured as a function of LY permeability in 
the presence of compounds 1, 12, 13, 14, and 16 at different concentrations. Increase in 
LY permeability in presence of the tested compound is an indication of loss of 
endothelial monolayer integrity. See experimental part for details. Data represent means 
of 3 independent culture inserts per condition. 
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Figure 2. Permeability values of compound 1 and its N-OMe (12), N-OEt (13), and N-
OH (16) analogues compared to LY. Permeability values are represented as a 
percentage of the permeability value of LY (normalized to 100%). Data represent means 
of 3 independent culture inserts per condition. 
 
Discussion 
Dicationic drugs are very effective antimicrobial agents that have been used for the 
treatment of African trypanosomiasis and leishmaniasis for decades. Despite their 
excellent antiparasitic activity this kind of drugs presents a major drawback, namely a 
poor absorption through biological barriers such as the gastrointestinal tract or the BBB 
(e.g., the diamidine drugs pentamidine, berenil or furamidine are not orally active and 
do not cure late-stage HAT). Lowering the pKa of the amidine moiety by attaching OR 
groups (R = H, alkyl) to the nitrogen atoms to generate orally active prodrugs has been a 
successful strategy in a number of cases.11, 13, 21, 41 Our objective was the study of N-
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alkoxy derivatives of a dicationic bisaminoimidazolinyl trypanocidal lead compound, 1,  
showing the same drawback as the above mentioned diamidines.  
As expected for a prodrug requiring in vivo metabolic activation, the N-alkoxy 
derivatives displayed reduced activity (in the submicromolar range) in the parasite 
susceptibility assay in vitro. Furthermore, one of the new N-alkoxy derivatives, 16, was 
active in vivo in the STIB900 mouse model after intraperitoneal administration. Even 
though this moderate effect could be attributed to the fair intrinsic activity observed in 
vitro for this compound (IC50 = 0.37 µM), it is likely due to a partial bioactivation of 16 
to the lead compound 1. In fact, the 2-aminoimidazolinyl moiety can be viewed as a 
cyclic guanidine42 and the in vivo reduction of N-hydroxylated guanidines and amidines 
by microsomes and mitochondria of different organs from different species (e.g., 
kidney, liver, brain) has been established before.12, 43, 44 This result is important because 
it is compound 16 that showed the highest in vitro BBB permeability in our assays. The 
in vivo activity of 16 in the mouse model of CNS-stage infection was not yet tested 
because of its limited efficacy in the acute STIB900 model. However, the synthesis of 
this class of prodrugs with more potent lead candidates is warranted.  
On the one hand, the lack of in vivo activity of the alkoxy derivatives 12, 13 and 14, 
despite of similar inherent activities in vitro (IC50 values of 0.83, 0.73, and 0.32 µM, 
respectively), may possibly be attributed to a poor bioactivation. As far as we know, the 
bioactivation of N-alkoxy prodrugs has been described for amidines but not for 
guanidines.On the other hand, this might be explained by a high fraction of protein 
binding or other unfavourable pharmacokinetics.  
The Pe values measured in vitro with the human brain endothelial cell line hCMEC/D3 
for the lead compound 1, and the O-alkyl substituted derivatives 12 and 13, were 
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comparable to the Pe values of the control molecule LY that presents a very low brain 
uptake (see experimental section for more details). Thus, compound 1 scarcely 
penetrates the BBB which possibly explains why this molecule is inactive in the murine 
model of late-stage HAT.9 The derivatization of the imidazoline nitrogen with OMe or 
OEt did not improve the BBB permeability whereas a free OH group increased the 
permeability by almost 3-fold compared with the lead compound 1. In comparison, the 
benzodiazepine drug diazepam that is used as anxiolytic and has large BBB uptake45 
shows 10-fold higher permeability than LY using the hCMEC/D3 cell line (data not 
shown). This means that compound 16 shows an intermediate in vitro permeability to 
the brain. 
This result was somewhat unexpected as increasing the number of hydrogen bond 
donors and the polar surface area is generally associated with a reduced BBB 
permeability.46 To try rationalize these results, we calculated some physicochemical 
parameters that are generally accepted as important for a compound to be readily BBB 
permeable (Table 3).47 The molecular hydrophobicity of a compound, measured as the 
octanol/water partition coefficient (logP), is an important physicochemical property 
associated with biological membrane permeation. For ionizable molecules to be BBB 
permeable, values of octanol/water distribution coefficients, logD7.4, in the range 
between 1 and 3 are recommended.48 As shown in Table 3, two compounds only, 12 
and 16, have logD7.4 values within this range. Thus, adequate hydrophobicity and low 
pKa values may explain the enhanced in vitro BBB permeability observed for 16. 
However, these data do not explain the low permeability of 12 measured in vitro. Taken 
togrether, these findings show that subtle modification of the nitrogen substituent (e.g., 
OH ↔ OMe) greatly affects the BBB permeability of the bis-2-imidazolinylamino 
compounds.   
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Table 3. Calculated physicochemical parameters of the compounds: molecular weight 
(MW), polar surface area (PSA), octanol/water distribution coefficient at pH 7.4 (log 
D7.4), H-bond donors (HBD), and pKa. 
Cmpd MWa PSAb log D7.4
b pKa (N3; N3’)
 b,c HBDd 
1
e
 408.33 88.09 0.1 8.02; 8.63 5 
12 395.46 85.75 2.51 5.73; 6.34 3 
13 423.51 85.75 3.22 5.81; 6.41 3 
14 547.65 85.75 5.95 5.77; 6.37 3 
15 535.64 104.21 4.31 5.85; 6.45 3 
16 367.40 107.75 1.76 5.64; 6.24 5 
17
 369.51 60.81 3.92 6.76; 7.37 3 
a Molecular weight (g/mol). b The polar surface area (Å2), LogD7.4 and pKa were 
calculated using ChemAxon software MarvinSketch v.5.3.8. c Calculated pKa values of 
the N3-nitrogen of the imidazoline rings. d Number of H-bond donors. e Dihydrochloride 
salt. 
 
Conclusions 
Several N-alkoxy analogues of compound 1 were designed to reduce the basicity of the 
aminomidazolinyl groups and potentially improve the oral and CNS absorption of that 
trypanocidal lead compound. Four of these derivatives showed submicromolar IC50 
values in vitro against T. brucei and P. falciparum, but only one compound, the N-
hydroxy-2-imidazolylamino analogue 16, displayed moderate activity in vivo in the T. 
brucei STIB900 murine model at a dosage of 20mg/kg ip. This modest activity is 
possibly due to an incomplete bioactivation of the prodrug in vivo that does not permit 
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to reach the curative dose of the active compound. Even though other pharmacokinetic 
aspects such as plasma protein binding cannot be ruled out at this time, the in vivo 
activity displayed by 16 means that a substantial fraction of the active compound is 
unbound and free to reach its target in vivo. Further work to fully understand the 
pharmacokinetics of these compounds will be needed but this shall be the subject of a 
different study. 
More importantly, this compound also had the highest BBB permeability of the series 
(i.e., almost 3-fold increase with respect to lucifer yellow) in the in vitro transport assay 
involving the human brain endothelial cell line hCMEC/D3. These results suggest that 
N-hydroxy-2-imidazolylamino analogues may possibly be used as prodrugs of the 
imidazolylamino group with enhanced BBB penetration. Efforts are ongoing towards 
the discovery of more potent drugs able to cross the BBB for the treatment of late-stage 
HAT. 
 
Experimental section 
 Chemistry. All dry solvents were purchased from Aldrich (Sigma-Aldrich Quimica 
SA, Madrid, Spain) in Sure/Seal bottles. All reactions requiring anhydrous conditions or 
an inert atmosphere were performed under a positive pressure of N2. All reactions were 
monitored by Thin Layer Chromatography (TLC) using silica gel 60 F254 plates (Merck-
España, Madrid, Spain) or HPLC–MS. Chromatography was performed with Isolute SI 
prepacked columns (Biotage). 1H and 13C NMR spectra were recorded on a Bruker 
Advance 300 or Varian Inova 400 spectrometer. Chemical shifts of the 1H NMR spectra 
were internally referenced to the residual proton resonance of the deuterated solvents: 
CDCl3 (7.26 ppm), D2O (δ 4.6 ppm), CD3OD (3.49 ppm) and DMSO-d6 (δ 2.49 ppm). J 
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values are given in Hz. Melting points were determined in open capillary tubes with a 
SMP3–Stuart Scientific apparatus and are uncorrected. All compounds are >95% pure 
by HPLC or combustion analysis otherwise noted. Elemental analysis was performed on 
a Heraeus CHN–O Rapid analyser. Analytical results were within ± 0.4% of the 
theoretical values unless otherwise noted. Analytical HPLC–MS was run with an 
Xbridge C18–3.5 µm (2.1×100mm) column on a Waters 2695 separation module 
coupled with a Waters Micromass ZQ spectrometer using electrospray ionisation (ES+). 
The following HPLC conditions were used: column temperature = 30 ºC, gradient time 
= 15 min, H2O/CH3CN (5:95 → 95:5) (HCO2H 0.1%), flow rate = 0.25 mL/min, UV 
detection: diode array (λ = 190−400 nm).  
 1. First synthetic route for the synthesis of 1-alkoxy-2-arylaminoimidazolines 12 
and 14. 
 Bis(4-isothiocyanatophenyl)amine (3). The free diamine was obtained from 
technical grade 4,4’-diaminodiphenylamine sulphate as described earlier.49 
Thiophosgene (1.67 mL, 21.9 mmol) [CAUTION: wear adequate protection and work 
in a well ventilated fumehood] was added with a syringe to a mechanically stirred 
mixture of 4,4’-diaminodiphenylamine (1.985 g, 10 mmol) in 80 mL of Et2O/H2O (3/1 
v/v). The reaction was almost instantaneous. The mixture was stirred vigorously 
overnight and the precipitate was collected by filtration to give the isothiocyanate 3 as a 
greenish solid (1.58 g, 56%). Another crop was recovered from the filtrate (0.85 g, 
30%); mp 182–183 ºC; 1H NMR (CDCl3, 300 MHz) δ 7.15 (d, J = 8.8, 4H), 7.00 (d, J = 
8.8, 4H), 5.86 (br, NH, 1H); 13C NMR (CDCl3, 300 MHz) δ 139.2 (C), 132.5 (NCS), 
125.3 (CH), 122.6 (C), 117.6 (CH); Anal. (C14H9N3S2) C, H, N.  
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 2-(2-(Benzyloxyamino)ethyl)isoindoline-1,3-dione (4).
33, 34
 A mixture of O-
benzylhydroxylamine hydrochloride (12.71 mmol, 2.03 g, 1 equiv.), sodium hydroxide 
5% solution (25 mL) and diethyl ether (Et2O) (75 mL) was stirred for 15 min. The 
organic layer was extracted, dried over MgSO4 and evaporated under vacuum to give 
the free base of O-benzylhydroxylamine (BnONH2) as colorless oil (1.59 g, 100%). A 
mixture of BnONH2 (1.59 g, 12.68 mmol, 2 equiv.) and 2-bromoethylphthalimide (1.61 
g, 6.34 mmol, 1 equiv.) was heated at 80 ºC for 4 days. Ethyl acetate (EtOAc) was 
added to the cold reaction and the precipitate was filtered off. The filtrate was 
concentrated under vacuum to give a yellow oil. Recrystallization from MeOH yielded 
white crystals (433 mg, 23%): Rf  = 0.38 (hexane/EtOAc 2:1); mp (MeOH) 83–85 ºC 
(with previous softening) [lit.33 92–94 ºC]. 1H NMR (CDCl3, 300 MHz) δ 7.84–7.68 (m, 
4H, ArHPht), 7.36–7.25 (m, 5H, ArH), 5.63 (s, 1H, NH), 4.69 (s, 2H, CH2O), 3.89 (t, J = 
5.7, 2H, NCH2), 3.20 (t, J = 6.0, 2H, CH2NH). 
13C NMR (CDCl3, 300 MHz) δ 168.9 
(CO), 138.1 (C-1, Ar), 134.3 (CH, Pht), 132.6 (C, Pht), 129.4 (CH-4, Ar), 129.3 (CH-3, 
Ar), 128.2 (CH-2, Ar), 123.5 (CHCO, Pht), 76.3 (OCH2), 50.4 (CH2NH), 36.6 (NCH2). 
LRMS (ES+) m/z = 297.0 [(M+H), 100%]; Anal (C17H16N2O3) C, H, N. 
 2-(2-(Methoxyamino)ethyl)isoindoline-1,3-dione (5a). N,N-Diisopropylethylamine 
(DIPEA) (3.7 mmol, 0.6 mL, 2 equiv.) was added to O-methylhydroxylamine 
hydrochloride (3.7 mmol, 307 mg, 2 equiv.) in acetonitrile under N2 atmosphere. The 
mixture was stirred for few minutes and 2-bromoethylphthalimide (1.8 mmol, 467 mg, 1 
equiv.) was added. The reaction was heated at 80 ºC for 43 h. The cold reaction mixture 
was diluted with EtOAc and the precipitate was filtered off. The filtrate was 
concentrated under vacuum to give a yellow oil. Purification by flash chromatography 
with hexane/EtOAc (9:1) yielded the product as a white solid (80 mg, 20%): Rf = 0.26 
(hexane/EtOAc 2:1); mp 78–80 ºC. 1H NMR (CDCl3, 300 MHz) δ 7.85–7.68 (m, 4H, 
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ArHPht), 5.63 (t, 1H, NH), 3.88 (t, J = 5.7, 2H, NCH2), 3.51 (s, 3H, OCH3), 3.19 (q, J = 
5.7, 2H, CH2NH). 
13C NMR (CDCl3, 300 MHz) δ 168.8 (CO), 134.4 (CH, Pht), 132.5 
(C, Pht), 123.7 (CH, Pht), 62.4 (OCH3), 49.9 (CH2NH), 35.9 (NCH2). LRMS (ES
+) m/z 
= 221.0 [(M+H), 100%]. Anal (C11H16N2O5·2H2O) calcd: C, 51.56; H, 6.29; N, 10.93. 
Found: C, 51.74; H, 4.90; N, 11.39. 
 1,1´-(4,4´-Azanediylbis(4,1-phenylene))bis(3-(benzyloxy)-3-(2-(1,3-
dioxoisoindolin-2-yl)ethyl)thiourea) (6). Compound 4 (860 mg, 2.9 mmol, 2.5 equiv.) 
was added to the isothiocyanate 3 (329 mg, 1.7 mmol, 1 equiv.) in dry N,N-
dimethylformamide (DMF) (5 mL). The reaction mixture was stirred 4 days at room 
temperature. The solvent was evaporated and the resulting yellow oil was purified by 
flash chromatography (10g SI cartridge) with Hexane/EtOAc: 4/1→1/1. Further 
rerystallization from EtOAc/hexane yielded 6 as a yellow solid (427 mg, 42%): Rf = 
0.26 (EtOAc/hexane 1:1); mp 118–120 ºC (EtOAc/hexane). 1H NMR (300 MHz, 
CDCl3) δ 8.32 (s, 2H, PhNHCS), 7.79 (dd, J = 3.0 and 5.4, 2H, ArHPht), 7.65 (dd, J = 
3.0 and 5.4, 2H, ArHPht), 7.35–7.31 (m, 10H, ArHBn), 7.01 (d, J = 8.7, 4H, ArH), 6.90 
(d, J = 8.7, 4H, ArH), 5.85 (s, 1H, PhNHPh), 4.87 (s, 4H, OCH2Ph), 4.52 (t, J = 4.6, 
4H), 4.09 (t, J = 4.6, 4H). 13C NMR (75 MHz, CDCl3) δ 181.2 (CS), 168.2 (CO), 141.2 
(NHC), 133.9 (CCH2O+CHPht), 132.1 (CPht), 130.8 (CNHCS), 129.3 (CHm, Bn), 129.2 
(CHp, Bn), 128.8 (CHo, Bn), 126.8 (CH, aniline), 123.1 (CCHCH, Pht), 117.4 (CH, 
aniline), 60.3 (OCH2), 48.8 (CH2N), 34.8 (CH2N); LRMS (ES+) m/z 877.0 (M+H). Anal 
(C48H41N7O6S2) C, H, N.  
 1,1'-(4,4'-Azanediylbis(4,1-phenylene))bis(3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-3-
methoxythiourea) (7). Compound 7 was obtained as an orange solid (55 mg, 83%) by 
the same procedure used for 6: Rf = 0.74 (CH2Cl2/MeOH 95:5); mp 194–196 ºC 
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(decomp.). 1H NMR (300 MHz, DMSO–d6) δ 9.82 (s, 2H, NHCS), 8.10 (s, 1H, 
PhNHPh), 7.86–7.78 (m, 8H, Pht), 7.05 (d, J = 8.7, 4H, Ph), 6.92 (d, J = 8.7, 4H, Ph), 
4.38 (t, J = 4.7, 4H, CH2CH2), 3.90 (t, J = 4.7, 4H, CH2CH2), 3.68 (s, 6H, OCH3). 
13C 
NMR (75 MHz, DMSO–d6) δ 179.5 (CS), 168.1 (CO), 141.5 (NHC), 134.6 (CHPht), 
132.3 (CPht), 131.6 (CNHCS), 128.0 (CH, aniline), 123.3 (CHPht), 116.3 (CH, aniline), 
61.6 (OCH3), 47.7 (CH2N), 35.0 (CH2N). LRMS (ES+) m/z 724.10 [(M+H), 100%]. 
Anal (C36H33N7O6S2) C, H, N.  
 (N,N'Z,N,N'Z)-Dimethyl-N,N'-4,4'-azanediylbis(4,1-phenylene)bis(N-benzyloxy-
N-(2-(1,3-dioxoisoindolin-2-yl)ethyl)carbamimidothioate) (8). An excess of methyl 
iodide (2 mL) was added to a stirred solution of 6 (408 mg, 0.5 mmol) in CH2Cl2 (9 
mL). The mixture was stirred at room temperature for 6 days. Vacuum  evaporation of 
the solvents gave the product as a yellow solid (470 mg, quantitative). The product was 
pure enough to be used in the next reaction: Rf = 0.72 (EtOAc/Hexane 1:1); 
1H NMR 
(300 MHz, CDCl3) δ 7.85–7.73 (m, 8H, Pht), 7.39–7.30 (m, 10H, CH2Ph), 7.07 (m, 8H, 
Ph), 5.08 (s, 4H, OCH2Ph), 4.31 (t, 4H, CH2N), 4.04 (t, 4H, CH2N), 2.12 (s, 6H, SCH3); 
LRMS (ES+) m/z 904.5 (M+H). HPLC = 80% pure. 
 N
1
-(1-(Benzyloxy)-4,5-dihydro-1H-imidazol-2-yl)-N
4
-(4-(1-(benzyloxy)-4,5-
dihydro-1H-imidazol-2-ylamino)phenyl)benzene-1,4-diamine (14). An excess of 
methylamine 2.0 M solution in THF (15 mL) was added to a solution of 8 (1.37 g, 1.5 
mmol) in H2O (10 mL). The reaction mixture was stirred for 24 h and evaporated to 
dryness. The oily residue was washed with H2O, filtered off and purified by flash 
chromatography with CH2Cl2/MeOH (97:3)  to yield the title compound as a brown 
solid (250 mg, 30%). Dihydroiodide salt of 14: mp 152–154 ºC (with previous 
softening). 1H NMR (300 MHz, CD3OD) δ 7.56–7.45 (m, 10H, CH2Ph), 7.23 (m, 8H, 
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Ph), 5.49 (s, 1H, NH), 5.10 (s, 4H, OCH2), 3.54 (s, 8H, CH2CH2). 
13C NMR (75 MHz, 
CD3OD) δ 162.3 (C=N), 144.6 (C; 4,4’-Ph), 136.6 (C, Bn), 130.9 (CHm, Bn), 130.2 
(CHp, Bn), 129.8 (CHo, Bn), 128.2 (C; 1,1’-Ph), 127.5 (CHPh), 119.2 (CHPh), 79.7 
(OCH2), 52.7 (BnONCH2), 42.1 (CH2N). LRMS (ES+) m/z 548.39 (M+H). Anal 
(C32H35I2N7O2· 2 H2O) calcd: C, 45.78; H, 4.68; N, 11.68. Found: C, 45.65; H, 2.87; N, 
12.09%. HPLC > 92% pure. 
 2. Second synthetic route for the synthesis of 1-alkoxy-2-arylaminoimidazolines 
12–16. The 1-methoxy- (12), 1-ethoxy- (13), 1-benzyloxy- (14) and 1-
tetrahydropyranyloxy- (15) derivatives were synthesised following the one-pot 
procedure previously reported by us. The products showed satisfactory spectroscopic 
and analytical data as reported previously.36 In separate experiments, the thiourea 
intermediates (10a and 10b) were also isolated and fully characterized. The 
spectroscopic data are given below. 
N,N'-(2,2'-(4,4'-Azanediylbis(4,1-phenylene)bis(azanediyl))bis(thioxomethylene)bis 
(azanediyl)bis(ethane-2,1-diyl))bis(N-methoxy-2-nitrobenzenesulfonamide) (10a). 
A solution of isothiocyanate 3 (0.30 mmol, 85 mg, 1 equiv.) in dry DMF (1 mL) was 
added to a solution of N-(2-aminoethyl)-N-methoxy-2-nitrobenzenesulfonamide (9, R1 = 
Me)36 (0.60 mmol, 277 mg, 2 equiv.) in dry DMF (5 mL). The resulting mixture was 
stirred at room temperature for 2 days. Water was added to give a precipitate that was 
filtered off. Purification by flash chromatography with hexane/ethyl acetate (1:1) 
yielded the product as a yellowish solid (67 mg, 27%): Rf  = 0.65 (EtOAc/hexane 8:2); 
mp (CH2Cl2) 120–122 ºC (with previous softening).  
1H NMR (CDCl3, 300 MHz) δ 8.01 
(d, J = 7.8, 2H, ArHNs), 7.85–7.67 (m, 4H, ArHNs), 7.75 (s, 2H, NHCS), 7.58 (d, J = 7.8, 
2H, ArHNs), 7.13 (m, 8H, ArH), 6.27 (t, J = 4.8, 2H, NHCH2), 6.07 (s, 1H, NH), 3.90 
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(m, 4H), 3.78 (s, 6H, OCH3), 3.35 (t, J = 4.4, 4H). 
13C NMR (CDCl3, 300 MHz) δ 181.7 
(CS), 150.0 (CNO2), 142.7 [ArC-NH), 135.7 (CH-5, Ns), 132.8 (CH-3, Ns), 131.7 (CH-
6, Ns), 128.9 (CSO2, Ns), 127.9 (CH-3, Ar), 126.2 (C-4, Ar), 124.2 (CH-4, Ns), 119.5 
(CH-2, Ar), 66.1 (OCH3), 52.4, 42.9. LRMS (ES
+) m/z = 833.7 [(M+H), 100%]. Anal 
(C32H35N9O10S4·3 H2O) calcd: C, 43.28; H, 4.65; N, 14.20; S, 14.44. Found: C, 43.86; 
H, 4.78; N, 14.05; S, 13.01. HPLC > 90% pure. 
 N,N'-(2,2'-(4,4'-Azanediylbis(4,1-phenylene)bis(azanediyl))bis(thioxomethylene) 
bis (azanediyl)bis(ethane-2,1-diyl))bis(N-ethoxy-2-nitrobenzenesulfonamide) (10b). 
A solution of isothiocyanate 3 (1.7 mmol, 329 mg, 1 equiv.) in dry DMF (1 mL) was 
added to a solution of N-(2-aminoethyl)-N-ethoxy-2-nitrobenzenesulfonamide36 (9, R1 = 
Et) (2.9 mmol, 860 mg, 2.5 equiv.) in dry DMF (5 mL). The reaction mixture was 
stirred for 4 days at room temperature. The solvent was evaporated to give a yellow oil 
that was purified by flash chromatography with hexane/EtOAc (1:1). Crystallization 
from EtOAc/Hexane yielded the product as yellow oil (427 mg, 42%): Rf = 0.83 
(EtOAc/hexane 1:1). 1H NMR (CDCl3, 300 MHz) δ 8.03 (dd, J = 7.7 and 1.35, 2H, 
ArHNs), 7.83–7.71 (m, 4H, ArHNs), 7.59 (dd, J = 7.78 and 1.0, 2H, ArHNs), 7.58 (s, 2H, 
NHCS), 7.14 (m, 8H, ArH), 6.24 (t, 2H, NHCH2), 5.94 (s, 1H, NH), 4.06 (q, J = 7.0, 4H, 
OCH2), 3.92 (m, 4H, NHCH2), 3.39 (t, J = 4.8, 4H, NCH2), 1.19 (t, J = 7.1, 6H, CH3). 
13C NMR (CDCl3, 300 MHz) δ 181.2 (CS), 149.5 (CNO2), 142.2 (ArC-NH), 135.2 (CH-
5, Ns), 132.4 (CH-3, Ns), 131.2 (CH-6, Ns), 128.4 (CSO2, Ns), 127.4 (CH-3, Ar), 125.9 
(C-4, Ar), 123.8 (CH-4, Ns), 119.1 (CH-2, Ar), 73.9 (OCH2), 52.1 (CH2), 42.5 (CH2), 
13.5 (CH3). LRMS (ES
+) m/z = 862.47 (M+H). HPLC > 90% pure. 
 4,4'-Bis(1-hydroxyimidazolinylamino)diphenylamine (16). The THP-protected 
product 1536 (80 mg, 0.15 mmol) was dissolved in MeOH (2 mL) and treated with HClg 
saturated dioxane solution (5 mL). The reaction was stirred at room temperature for 5 h 
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and the solvent was removed under vacuum. The crude product was dissolved in MeOH 
and Et2O was added. The flask was allowed to stand in the fridge overnight whereupon 
a precipitate settled at the bottom of the flask. The supernatant was discarded and Et2O 
was added. The precipitate was triturated with spatula, collected and dried under 
vacuum to give the dihydrochloride salt of 16 as brown solid (56 mg, 85%); mp > 91.4 
ºC (decomp.). 1H NMR (DMSO-d6) δ 10.94 (brs, 2H, OH), 10.62 (s, 2H, NH), 8.87 (s, 
2H, NH), 7.21 (d, J = 9.0, 4H, ArH-3), 7.16 (d, J = 9.0, 4H,  ArH-2), 3.82–3.46 (m, 8H). 
13C NMR (DMSO-d6) δ 160.8 (C=N), 142.7 (C), 126.9 (C), 126.4 (C), 117.6 (CH), 53.3 
(CH2), 40.6 (CH2). LRMS (ES
+) m/z 368.15 [(M+H)]. HPLC ≥ 95% pure. 
  4,4'-Bis(thiazolinylamino)diphenylamine (17).  Triethylamine (3.18 mmol, 0.44 
mL, 3 equiv.) was added dropwise to a solution of isothiocyanate 3 (1.06 mmol, 300 
mg, 1 equiv.) and 2-bromoethanamine hydrobromide (2.65 mmol, 543 mg, 2.5 equiv.) 
in CH2Cl2 (20 mL). The reaction mixture was stirred at room temperature overnight. 
The precipitate was collected by filtration, rinsed with dichloromethane and water, 
successively. Recrystallization from boiling methanol/acetonitrile yielded a green solid 
(92 mg, 15%): Rf = 0.22 (CH2Cl2/MeOH 2/1); mp 82–84 ºC (with previous softening). 
A methanolic solution of 17 (2 mL) was stirred with HClg saturated dioxane solution (3 
mL). The solvents were removed under vacuum affording the dihydrochloride salt of 
17: 1H NMR (DMSO-d6, 300 MHz) δ 8.64 (brs, 2H, NH), 7.67 (s, 1H, NH), 7.25 (d, J = 
7.9, 4H, ArH-2), 6.88 (d, J = 8.7, 4H, ArH-3), 3.85 (t, J = 7.1, 4H, NCH2), 3.24 (t, J = 
7.1, 4H, SCH2). 
13C NMR (DMSO-d6, 300 MHz) δ 157.2 (C=N), 138.9 (Ar, C-2), 137.1 
(Ar, C-4), 120.2 (Ar, 2-CH), 117.3 (Ar, 3-CH), 57.33 (CH2N), 32.9 (CH2S). LRMS 
(ES+) m/z = 369.9 [(M+H), 100%]. Anal (C18H19N5S2·2HCl·2H2O) C, H, N. HPLC > 
95% pure. 
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Biology. 
 In vitro BBB permeability studies. Cell line culture. Immortalized human brain 
endothelial cells (hCMEC/D3 cell line) were seeded at the density of 50,000 cells per 
cm2 in the upper compartment of six-well tissue culture plate inserts (Millicell CM 
inserts, 0.4 µm porosity, Millipore, Bellerica, MA, USA), pre-coated with rat tail 
collagen type I (Cultrex rat Collagen, R&D systems, Trevigen). They were then 
maintained for 10-12 days in EBM-2 basal medium (Lonza, Basel, Switzerland) 
containing 5% fetal bovine serum Gold (PAA, The Cell Culture Company, Pasching, 
Austria), 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA), 1.4 µM 
hydrocortisone (Sigma, St. Louis, MO, USA), 10 mM  HEPES (PAA Laboratories, 
Pasching, Austria), 5 µg mL− 1 ascorbic acid (Sigma, St Louis, MO, USA) and 1 ng mL− 
1 bFGF (Sigma, St Louis, MO, USA), at 37 °C in 5% CO2
  atmosphere. The medium 
was changed every 3–4 days. Twenty four hours prior to permeability assays, fresh 
medium was supplemented with Simvastatin 1 nM (Calbiochem, La Jolla, CA, USA). 
In summary, endothelial cells were cultured in Boyden chamber-like system allowing 
them to separate 2 compartments, the upper or luminal compartment and the lower or 
abluminal one, which represent the blood and the cerebral one, respectively. 
Permeability assays. Prior compound permeability study, it is essential to find a 
working concentration of the compounds that will not disturb the cellular complex 
between endothelial cells. For this purpose, endothelial monolayer quality was checked 
by following the passage of the small hydrophilic fluorescent molecule lucifer yellow 
(LY, Sigma, St Louis, MO, USA) when a fixed concentration of the studied compound 
(i.e., 12, 13, 14, or 16) was put on the cells in the luminal compartment. Note that LY is 
widely used and accepted as a marker of tight junction integrity.40 If LY permeability 
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was affected by the presence of the compound, the concentration of the compound was 
decreased until a non-affecting dose was reached.  
Compound 1 was directly dissolved in transport buffer whereas the N-alkoxy 
derivatives (12, 13, 14, and 16) were dissolved in DMSO (Sigma) and then diluted with 
transport buffer to reach a concentration of 100 µM. The maximum quantity of DMSO 
in the stock solutions was 0.1%. The endothelial monolayer integrity in presence of 
0.1% DMSO was checked, showing no significant difference compared with the buffer 
alone (See Figure 1).  
So, briefly after 10-12 days of culture, coated culture inserts with and without 
endothelial cell were transferred to 6-well plates containing 2 mL of transport buffer 
(Hanks buffer saline solution with CaCl2 and MgCl2, 10 mM HEPES and 1 mM sodium 
pyruvate) in the abluminal chamber. At time 0, transport buffer, containing tested 
compound with or without LY (50 µM dissolved in cell culture tested water), was 
placed in each luminal chamber. Transport incubations occured at 37 °C, 95% humidity 
and 5% CO2. At different times: 10, 25 and 45 min, each culture insert (with and 
without cell) was transferred to a new lower compartment containing fresh transport 
buffer. The amount of each compound in the lower compartments at different time 
points, in the upper one at the end of the experiment, and in the working solution was 
quantified either by fluorimetry (for LY) or by HPLC–MS (for compounds 12 ,13, 14, 
and 16).  
Endothelial permeability was calculated from the clearance rate and the surface area, as 
previously described.38, 39 In this way, a concentration-independent permeability value 
was obtained. The increment in cleared volume between successive sampling events is 
calculated by dividing the amount of solute during the interval time by the donor 
chamber concentration, which is the luminal one in this study, as described below: 
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The total cleared volume at each time point is calculated by summing the incremental 
cleared volumes up to the given time point: 
Clearance (mL) = X/Cd 
Where X is the amount of drug in the receptor chamber (the abluminal one) and Cd is 
the donor chamber concentration at each time-point. The average volume cleared is 
plotted versus time, and the slope estimated by linear regression analysis, which allows 
calculating total endothelial monolayer permeability noted PSe: 
1 / PSe = 1 / PSt – 1 / PSf  and Pe = PSe / A, 
where PSe is the permeablitiy–surface area product value for the endothelial cell 
monolayer, A is the surface area of the filter (in cm2), PSt and PSf are the slopes of the 
clearance curves for the cell monolayer on coated culture insert filter and for the coated 
culture insert filter alone (meaning without cell monolayer), respectively. The PSe 
values are divided by the surface area (A, in cm2) of the culture insert to generate the 
endothelial permeability coefficient (Pe, in cm per min). These Pe values allow 
classifying the molecules into 3 categories: low-, intermediate- or high-brain uptake.  
Compound permeability values were expressed as an increase or decrease compared  
with a model of low brain uptake, LY permeability (Pe = 3.04 × 10
-3 cm/min), which is 
given the value of 100%. LY was chosen as paracellular diffusion marker because of its 
properties: it is a small (457.3 Da) and hydrophilic molecule that has no transporter on 
endothelial cells (data not shown). 
 HPLC analysis of the results. 1 mL samples for each time point were taken directly 
from the basal compartment and transferred to 1.5 mL Waters HPLC vials that were 
stored in the freezer. The samples were defrost and shaken with an orbital shaker for 20 
min just before running the HPLC analysis. Analytical HPLC–MS was run with a 
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Waters Sunfire C18–3.5 µm (4.6×50mm) column on a Waters 2695 separation module 
coupled with a Waters Micromass ZQ spectrometer using electrospray ionization (ES+). 
The following HPLC conditions were used: column temperature = 30 ºC, flow rate = 1 
mL/min, gradient time = 5 min, the solvent mixture was H2O:CH3CN (HCO2H 0.1%%) 
with the following proportions: compound 1 (100:0 → 90:10), compound 12 (98:2 → 
50:50), compounds 13 and 14 (95:5 → 50:50), and compound 16 (98:2 → 70:30). The 
compounds were detected by UV at the following wavelengths: λ = 296 nm (compound 
1), 300 nm (compounds 12 and 13), 303 nm (compound 14), and 298 nm (compound 
16). Each sample was injected 3 times and the mean value of the compound UV peak 
area was used to determine the concentration of the sample according to the calibration 
curves. Calibration curves were obtained for each compound using 6 different 
concentrations (1, 10, 30, 75, 150, 375 µM). Each concentration was tested in triplicate 
and the mean value of the compound UV peak area vs. concentration was plotted. The 
equation for the calibration curve was obtained by linear regression analysis using the 
Microsoft Excel program. 
 In vitro antiprotozoal activity. IC50 values against bloodstream forms of T. b. 
rhodesiense strain STIB900, amastigotes of L. donovani strain MHOM/ET/67/L82, and 
cytotoxicity on rat myoblasts L-6 cells  were determined using the Alamar blue assay.50, 
51 IC50 values against erythrocytic stages of P. falciparum was determined by a 
[3H]hypoxanthine incorporation assay using the chloroquine- and pyrimethamine-
resistant strain K1.52 IC50 values against trypomastigote forms of T. cruzi Tulahuen 
strain C2C4 containing the β-D-galactosidase (LacZ) gene were determined using a 
colorimetric assay with the substrate chlorophenyl red β-D-galactopyranoside (CPRG)-
Nonidet.53 Detailed experimental protocols for all of these assays have been reported 
before.37 
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 In vivo antitrypanosomal activity. The STIB900 acute mouse model mimics the 
first stage of the disease. Experiments were performed as previously reported,16 with 
minor modifications. Briefly, female NMRI mice were infected intraperitoneally (i.p.) 
with 2 x 104 bloodstream forms of T. b. rhodesiense (strain STIB900). Experimental 
groups of four mice were treated i.p. or orally (per os [p.o.]) with compounds on four 
consecutive days from day 3 to 6 postinfection. A control group was infected but 
remained untreated. The tail blood of all mice was checked for parasitemia until 60 days 
after infection. Surviving and aparasitemic mice at day 60 were considered cured and 
then euthanized. The day of death of the animals was recorded (including the cured 
mice, as >60) to calculate the mean survival time in days (MSD). Mean relapse days 
were determined as day of relapse post-infection of mice. All protocols and procedures 
used in the current study were reviewed and approved by the local veterinary authorities 
of the Canton Basel-Stadt. 
 Acknowledgements. This work was supported by grants from the Spanish 
Ministerio de Ciencia e Innovación (Grants SAF2006-04698, SAF2009-10399), and the 
CSIC (Grant PIE 200680I121, bilateral projects grant 2008GB0021 and PA1002103) to 
C.D., the UNDP/World Bank/WHO Special Program for Research and Training in 
Tropical Diseases (R.B.). We gratefully acknowledge the IQM Mass Spectrometry 
Service Centre for HPLC-MS analysis and Dr. Angel de la Puerta for helpful 
discussions regarding HPLC analytical methods. C.R. was recipient of a PhD fellowship 
for the government of Panama (SENACYT grant BIDP-2008-030), Florence Miller was 
supported by EUSTROKE 7th framework programme theme health-2007-2.4.2-3, 
Combating Stroke. Thanks are given to Dr. Pierre-Olivier Couraud for logistic 
collaboration and proofreading of the manuscript. We thank Dr. Raj Chari for kindly 
revising the English of this manuscript.  
 31 
References 
1. http://www.dndi.org/diseases/hat/global-view.html (25th November 2009). 
2. WHO. Human African trypanosomiasis (sleeping sickness): epidemiological 
update. Wkly Epidemiol Rec 2006, 81, 71-80. 
3. WHO. Control and Surveillance of African Trypanosomiaisis.; WHO technical 
report series, vol. 881: Geneva, 1998; pp 1-113. 
4. Rodgers, J. Human African trypanosomiasis, chemotherapy and CNS disease. J. 
Neuroimmunol. 2009, 211, 16-22. 
5. Barrett, M. P.; Boykin, D. W.; Brun, R.; Tidwell, R. R. Human African 
trypanosomiasis: pharmacological re-engagement with a neglected disease. Br. J. 
Pharmacol. 2007. 
6. Dardonville, C.; Brun, R. Bisguanidine, bis(2-aminoimidazoline), and polyamine 
derivatives as potent and selective chemotherapeutic agents against Trypanosoma 
brucei rhodesiense. Synthesis and in vitro evaluation. J. Med. Chem. 2004, 47, 2296-
2307. 
7. Rodríguez, F.; Rozas, I.; Kaiser, M.; Brun, R.; Nguyen, B.; Wilson, W. D.; 
García, R. N.; Dardonville, C. New Bis(2-aminoimidazoline) and Bisguanidine DNA 
Minor Groove Binders with Potent in Vivo Antitrypanosomal and Antiplasmodial 
Activity. J. Med. Chem. 2008, 51, 909-923. 
8. Glass, L. S.; Nguyen, B.; Goodwin, K. D.; Dardonville, C.; Wilson, W. D.; 
Long, E. C.; Georgiadis, M. M. Crystal Structure of a Trypanocidal 4,4'-
Bis(imidazolinylamino)diphenylamine Bound to DNA. Biochemistry 2009, 48, 5943-
5952. 
 32 
9. Dardonville, C.; Barrett, M. P.; Brun, R.; Kaiser, M.; Tanious, F.; Wilson, W. D. 
DNA binding affinity of bisguanidine and bis(2-aminoimidazoline) derivatives with in 
vivo antitrypanosomal activity. J. Med. Chem. 2006, 49, 3748-3752. 
10. Kinsella, G. K.; Rodriguez, F.; Watson, G. W.; Rozas, I. Computational 
approach to the basicity of a series of [alpha]1-adrenoceptor ligands in aqueous 
solution. Bioorg. Med. Chem. 2007, 15, 2850-2855. 
11. Riggs, J. R.; Kolesnikov, A.; Hendrix, J.; Young, W. B.; Shrader, W. D.; 
Vijaykumar, D.; Stephens, R.; Liu, L.; Pan, L.; Mordenti, J. Factor VIIa inhibitors: A 
prodrug strategy to improve oral bioavailability. Bioorg. Med. Chem. Lett. 2006, 16, 
2224-2228. 
12. Clement, B.; Mau, S.; Deters, S.; Havemeyer, A. Hepatic, extrahepatic, 
microsomal, and mitochondrial activation of the N-hydroxylated prodrugs 
benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-
[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4- piperidinyl]oxy]-acetic 
acid). Drug Metab. Dispos. 2005, 33, 1740-7. 
13. Clement, B. Reduction of N-hydroxylated compounds: amidoximes (N-
hydroxyamidines) as pro-drugs of amidines. Drug Metab. Rev. 2002, 34, 565-79. 
14. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Prodrugs 
for aromatic bis-amidines: Anti-pneumocystis activity of bis-amidoximes and bis-
alkylamidoximes. Abstracts of Papers of the American Chemical Society 1997, 214, 
162-Medi. 
15. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-
pneumocystis activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg. 
Med. Chem. Lett. 1996, 6, 3017-3020. 
 33 
16. Thuita, J. K.; Karanja, S. M.; Wenzler, T.; Mdachi, R. E.; Ngotho, J. M.; Kagira, 
J. M.; Tidwell, R.; Brun, R. Efficacy of the diamidine DB75 and its prodrug DB289, 
against murine models of human African trypanosomiasis. Acta Tropica 2008, 108, 6-
10. 
17. Mdachi, R. E.; Thuita, J. K.; Kagira, J. M.; Ngotho, J. M.; Murilla, G. A.; 
Ndung'u, J. M.; Tidwell, R. R.; Hall, J. E.; Brun, R. Efficacy of the novel diamidine 
compound 2, 5-bis (4-amidinophenyl)-furan-bis-O-methlylamidoxime (pafuramidine, 
DB289) against T. b. rhodesiense infection in vervet monkeys after oral administration. 
Antimicrob. Agents Chemother. 2008, AAC.00831-08. 
18. Huang, T. L.; Bacchi, C. J.; Kode, N. R.; Zhang, Q.; Wang, G.; Yartlet, N.; 
Rattendi, D.; Londono, I.; Mazumder, L.; Vanden Eynde, J. J.; Mayence, A.; Donkor, I. 
O. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, 
an orally active prodrug. Int. J. Antimicrob. Agents 2007, 30, 555-561. 
19. Ismail, M. A.; Brun, R.; Easterbrook, J. D.; Tanious, F. A.; Wilson, W. D.; 
Boykin, D. W. Synthesis and antiprotozoal activity of aza-analogues of furamidine. J. 
Med. Chem. 2003, 46, 4761-9. 
20. Wenzler, T.; Boykin, D. W.; Ismail, M. A.; Hall, J. E.; Tidwell, R. R.; Brun, R. 
New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In 
Vivo Efficacy of Aza Analogs of DB289. Antimicrob. Agents Chemother. 2009, 53, 
4185-4192. 
21. Weller, T.; Alig, L.; Beresini, M.; Blackburn, B.; Bunting, S.; Hadvary, P.; 
Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller, M.; 
Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally active 
fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. 
1996, 39, 3139-47. 
 34 
22. Degardin, M.; Wein, S.; Durand, T.; Escale, R.; Vial, H.; Vo-Hoang, Y. N-
substituted bis-C-alkyloxadiazolones as dual effectors: efficient intermediates to 
amidoximes or amidines and prodrug candidates of potent antimalarials. Bioorg. Med. 
Chem. Lett. 2009, 19, 5233-6. 
23. Reeh, C.; Wundt, J.; Clement, B. N,N'-Dihydroxyamidines: A New Prodrug 
Principle To Improve the Oral Bioavailability of Amidines. J. Med. Chem. 2007. 
24. Dennis, S.; Joscha, K.; Helen, H.; Jürke, K.; Bernd, C. The Peptidylglycine 
alpha-Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes 
and N-Hydroxyguanidines? ChemMedChem 2009, 4, 1595-1599. 
25. Clement, B.; Burenheide, A.; Rieckert, W.; Schwarz, J. 
Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal 
diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem 2006, 1, 
1260-7. 
26. Grimmett, M. R. Imidazoles and their benzo derivatives: (ii) Reactivity. In 
Comprehensive Heterocyclic Chemistry, Pergamon: 1984; Vol. 5, p 384. 
27. Metzger, J. V. Thiazoles and their benzo derivatives. In Comprehensive 
Heterocyclic Chemistry, Pergamon: 1984; Vol. 6, p 252. 
28. Poller, B.; Gutmann, H.; Krähenbühl, S.; Weksler, B.; Romero, I.; Couraud, P.-
O.; Tuffin, G.; Drewe, J.; Huwyler, J. The human brain endothelial cell line hCMEC/D3 
as a human blood-brain barrier model for drug transport studies. J. Neurochem. 2008, 
107, 1358-1368. 
29. Weksler, B. B.; Subileau, E. A.; Perriere, N.; Charneau, P.; Holloway, K.; 
Leveque, M.; Tricoire-Leignel, H.; Nicotra, A.; Bourdoulous, S.; Turowski, P.; Male, D. 
K.; Roux, F.; Greenwood, J.; Romero, I. A.; Couraud, P. O. Blood-brain barrier-specific 
properties of a human adult brain endothelial cell line. FASEB J. 2005, 19, 1872-1874. 
 35 
30. Cucullo, L.; Couraud, P.-O.; Weksler, B.; Romero, I.-A.; Hossain, M.; Rapp, E.; 
Janigro, D. Immortalized human brain endothelial cells and flow-based vascular 
modeling: a marriage of convenience for rational neurovascular studies. J. Cereb. Blood 
Flow Metab. 2007, 28, 312-328. 
31. Dauchy, S.; Miller, F.; Couraud, P. O.; Weaver, R. J.; Weksler, B.; Romero, I. 
A.; Scherrmann, J. M.; De Waziers, I.; Decleves, X. Expression and transcriptional 
regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral 
microvascular endothelial cells. Biochem. Pharmacol. 2009, 77, 897-909. 
32. Hill, S. V.; Thea, S.; Williams, A. Degradation in aqueous solution of O-aryl N-
arylthioncarbamates to aryloxide ions and isothiocyanates. A study of Leffler's 
assumption. J. Chem. Soc., Perkin Trans. 2 1983, 437 - 446. 
33. Ramuz, H. 2-imino-imidazolidine derivatives. U.S. Patent 4,244,957, 1978. 
34. Alanine, A.; Bourson, A.; Buttelmann, B.; Gill, R.; Heitz, M. P.; Mutel, V.; 
Pinard, E.; Trube, G.; Wyler, R. 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a 
novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. 
Chem. Lett. 2003, 13, 3155-9. 
35. Greene, T. W.; Wuts, P. G. M. Protective groups in organic synthesis. 3rd ed.; 
Wiley Intersciences: 1999. 
36. Mascaraque, A.; Nieto, L.; Dardonville, C. Efficient one-pot synthesis of 1-
alkoxy-2-arylaminoimidazolines from N-alkoxy-N-(2-aminoethyl)-2-
nitrobenzenesulfonamides and arylisothiocyanates. Tetrahedron Lett. 2008, 49, 4571-
4574. 
37. Dardonville, C.; Fernandez-Fernandez, C.; Gibbons, S. L.; Jagerovic, N.; Nieto, 
L.; Ryan, G.; Kaiser, M.; Brun, R. Antiprotozoal activity of 1-phenethyl-4-
aminopiperidine derivatives. Antimicrob. Agents Chemother. 2009, 53, 3815-21. 
 36 
38. Cecchelli, R.; Dehouck, B.; Descamps, L.; Fenart, L.; Buée-Scherrer, V.; 
Duhem, C.; Lundquist, S.; Rentfel, M.; Torpier, G.; Dehouck, M. P. In vitro model for 
evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 
36, 165-178. 
39. Siflinger-Birnboim, A.; del Vecchio, P. J.; Cooper, J. A.; Blumenstock, F. A.; 
Shepard, J. M.; Malik, A. B. Molecular sieving characteristics of the cultured 
endothelial monolayer. J. Cell. Physiol. 1987, 132, 111-117. 
40. Deli, M.; Ábrahám, C.; Kataoka, Y.; Niwa, M. Permeability Studies on In Vitro 
Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology. Cell. Molec. 
Neurobiol. 2005, 25, 59-127. 
41. Hall, J. E.; Kerrigan, J. E.; Ramachandran, K.; Bender, B. C.; Stanko, J. P.; 
Jones, S. K.; Patrick, D. A.; Tidwell, R. R. Anti-Pneumocystis activities of aromatic 
diamidoxime prodrugs. Antimicrob. Agents Chemother. 1998, 42, 666-74. 
42. Dardonville, C.; Rozas, I.; Alkorta, I. Similarity studies on guanidinium, 
imidazolinium, and imidazolium cations: toward new bradykinin antagonists. J. Mol. 
Graph. Model. 1998, 16, 150-6, 166-7. 
43. Clement, B.; Lomb, R.; Moller, W. Isolation and characterization of the protein 
components of the liver microsomal O2-insensitive NADH-benzamidoxime reductase. 
J. Biol. Chem. 1997, 272, 19615-20. 
44. Clement, B.; Demesmaeker, M.; Linne, S. Microsomal catalyzed N-
hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: 
characterization of the two reactions and genotoxic potential of guanoxabenz. Chem. 
Res. Toxicol. 1996, 9, 682-8. 
45. Perriere, N.; Yousif, S.; Cazaubon, S.; Chaverot, N.; Bourasset, F.; Cisternino, 
S.; Decleves, X.; Hori, S.; Terasaki, T.; Deli, M.; Scherrmann, J. M.; Temsamani, J.; 
 37 
Roux, F.; Couraud, P. O. A functional in vitro model of rat blood-brain barrier for 
molecular analysis of efflux transporters. Brain Res. 2007, 1150, 1-13. 
46. Hitchcock, S. A.; Pennington, L. D. Structure-Brain Exposure Relationships. J. 
Med. Chem. 2006, 49, 7559-7583. 
47. Mensch, J.; Oyarzabal, J.; Mackie, C.; Augustijns, P. In vivo, in vitro and in 
silico methods for small molecule transfer across the BBB. J. Pharm. Sci. 2009, 98, 
4429-4468. 
48. van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J. R.; Raevsky, 
O. A. Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and 
Shape, and H-Bonding Descriptors. J. Drug Target. 1998, 6, 151-165. 
49. Rozalska, I.; Kulyk, P.; Kulszewicz-Bajer, I. Linear 1,4-coupled oligoanilines of 
defined length: preparation and spectroscopic properties. New J. Chem. 2004, 28, 1235-
1243. 
50. Raz, B.; Iten, M.; Grether-Buhler, Y.; Kaminsky, R.; Brun, R. The Alamar Blue 
assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T. b. 
gambiense) in vitro. Acta Trop. 1997, 68, 139-47. 
51. O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue 
(resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. 
Biochem. 2000, 267, 5421-5426. 
52. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative 
assessment of antimalarial activity in vitro by a semiautomated microdilution technique. 
Antimicrob. Agents Chemother. 1979, 16, 710-718. 
53. Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Voorhis, W. C. Efficient 
technique for screening drugs for activity against Trypanosoma cruzi using parasites 
expressing beta-galactosidase. Antimicrob. Agents Chemother. 1996, 40, 2592-2597. 
 38 
 
 
 39 
Table of Contents graphic 
 
 
H
N
N
H
N
H
N
NN
N
RR
R = H, OH, OMe, OEt, OBn
R = H
(hCMEC/D3 in vitro model)
human BBB
R = OH 3-fold increase Pe
 
 
 
 
 
 
